You are here

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Last updated on December 17, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Tucson, Arizona, 85710 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Vasomotor Symptoms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Generally healthy, postmenopausal woman who seeks treatment for hot flushes.

- Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6
months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels
> 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without
hysterectomy). Hysterectomized without bilateral oophorectomy and with serum FSH
levels >40 mIU/mL.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of a seizure disorder other than a single childhood febrile seizure.

- History or presence of clinically important hepatic or renal disease or other medical
disease.

- Presence or recent history of major depressive disorder, bipolar disorder, psychotic
disorder, or generalized anxiety disorder requiring therapy.

NCT00401245
Pfizer
Completed
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Severe Vasomotor Symptom Associated With Menopause
NCT02792504
Females
20+
Years
Multiple Sites
Major Depressive Disorder, Vasomotor Symptoms
NCT01353963
All Genders
18+
Years
Multiple Sites
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study
Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause. Nausea is the most common adverse event that is observed in clinical studies and is the main reason for discontinuation during the first week of therapy. Other adverse events (headache, nausea, and dizziness) associated with DVS SR have been noted to occur when subjects abruptly discontinue the medication. The purpose of this study is to evaluate several titration and tapering regimens of DVS SR to ensure a better tolerability profile at the start and completion of treatment. In addition, this study will provide a long posttreatment follow-up to assess any symptoms after treatment is discontinued.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Vasomotor Symptoms
  • Drug: desvenlafaxine succinate sustained release
    Titration 100 mg
  • Drug: desvenlafaxine succinate sustained release
    Titration 50 mg
  • Drug: desvenlafaxine succinate sustained release
    Titration 25 mg, 50mg
  • Drug: desvenlafaxine succinate sustained release
    Titration 25 mg
  • Drug: Placebo
    Tapering placebo
  • Drug: desvenlafaxine succinate sustained release
    Tapering 50 mg, placebo
  • Drug: desvenlafaxine succinate sustained release
    Tapering 50 mg, 25 mg
  • Drug: desvenlafaxine succinate sustained release
    Tapering 50 mg QOD
  • Active Comparator: A
    Intervention: Drug: desvenlafaxine succinate sustained release
  • Active Comparator: B
    Intervention: Drug: desvenlafaxine succinate sustained release
  • Active Comparator: C
    Intervention: Drug: desvenlafaxine succinate sustained release
  • Active Comparator: D
    Intervention: Drug: desvenlafaxine succinate sustained release
  • Active Comparator: E
    Intervention: Drug: Placebo
  • Active Comparator: F
    Intervention: Drug: desvenlafaxine succinate sustained release
  • Active Comparator: G
    Intervention: Drug: desvenlafaxine succinate sustained release
  • Placebo Comparator: H
    Intervention: Drug: desvenlafaxine succinate sustained release
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
500
January 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Generally healthy, postmenopausal woman who seeks treatment for hot flushes.
  • Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy). Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL.

Exclusion Criteria:

  • History of a seizure disorder other than a single childhood febrile seizure.
  • History or presence of clinically important hepatic or renal disease or other medical disease.
  • Presence or recent history of major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder requiring therapy.
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00401245
3151A2-405
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now